Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
JCO Glob Oncol ; 8: e2200192, 2022 12.
Article in English | MEDLINE | ID: mdl-36542825

ABSTRACT

PURPOSE: Challenges to breast cancer control in low-and middle-income countries exist because of constrained access to care, including pathology services. Immunohistochemistry (IHC)-based estrogen receptor (ER) analysis is limited-nonexistent because of few and inadequately staffed and equipped pathology laboratories. We have identified Nw-hydroxy-L-Arginine (NOHA) as a blood-based biomarker to distinguish ER status in US patients with breast cancer. Here, we examine NOHA's clinical utility as an ER IHC alternative in Tanzanian patients. MATERIALS AND METHODS: Following informed consent, 70 newly diagnosed, known or suspected patients with breast cancer were enrolled at Kilimanjaro Christian Medical Center; basic, deidentified clinical and sociodemographic data were collected. For each, a needle prick amount of blood was collected on a Noviplex plasma card and stored at -80°C. Plasma cards and unstained tumor pathology slides were shipped regularly to US laboratories for NOHA, histologic and IHC analysis. NOHA and IHC assay operators were blinded to each other's result and patient clinical status. Paired NOHA and IHC results were compared. RESULTS: Slides from 43 participants were available for pathological analysis in the United States. Of those with confirmed malignancy (n = 39), 44%, 51%, 5% were ER-positive, ER-negative, and ER inconclusive, respectively. NOHA levels were available among 33 of 43 of those with pathological data and showed distinct threshold levels correlating 100% to tumor ER IHC and disease categorization where a level below 4 nM, from 4 to 8 nM, and above 8 nM signified ER-negative, ER-positive, and no cancer, respectively. CONCLUSION: The results are consistent with findings from US patients and suggest NOHA's clinical utility as an accessible IHC replacement in determining ER status among low-and middle-income country patients with breast cancer, promising to extend access to cost-efficient, available hormonal agents and improve outcomes.


Subject(s)
Breast Neoplasms , Humans , Female , Breast Neoplasms/diagnosis , Breast Neoplasms/therapy , Receptors, Estrogen , Tanzania , Biomarkers, Tumor , Immunohistochemistry
2.
Adv Med Sci ; 65(2): 424-428, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32919119

ABSTRACT

PURPOSE: We investigated Nw-hydroxy l-Arginine (NOHA) predictive response in serous ovarian carcinoma based on estrogen-hormone receptor expression status; and assessed the distinctive NOHA response between estrogen-receptor-negative (ER-) tumor subtypes of ovarian and breast cancer. MATERIALS/METHODS: Three-dimensional (3D) spheroids models of ER- and estrogen-receptor-positive (ER+) from breast and ovarian tumor, cultured for 9 weeks, were assayed for cellular levels of inducible nitric oxide synthase (NOS2), nitric oxide (as total nitrite) and l-Arginine, and compared to NOHA in culture medium. Statistical difference was set at p < 0.01. RESULTS: Nine-week in vitro studies showed a progressive NOHA reduction in culture medium by at least 0.4-0.8 fold, and 0.65-0.92 fold only in the ER- breast tumor and ER- ovarian tumor 3D spheroids, respectively; with increases in cellular NOS2 and nitric-oxide levels, by at least 1.0-2.45 fold in both ER- tumor subtype 3D spheroids (p < 0.01; n = 6). Within ER- subtypes, medium NOHA decreased by ≥ 38.9% in ovarian cancer over breast cancer 3D-spheroids, with cellular increases in NOS2 (by ≥ 17.4%), and nitric oxide (by ≥ 18.8%). Cellular l-Arginine to medium NOHA ratio was higher, and by at least 6.5-22.5 fold in ER- breast tumor 3D-spheroids, and at least 10-70 fold in ER- ovarian tumor 3D spheroids, than in ER+ and control conditions; and was ≥48% higher in ER- ovarian cancer than in ER- breast cancer 3D-spheroids. CONCLUSIONS: The present study shows NOHA as a sensitive and selective indicator differentiating and distinguishing ER- subtypes based on the tumor grade.


Subject(s)
Biomarkers, Tumor/metabolism , Breast Neoplasms/metabolism , Nitric Oxide Synthase Type II/metabolism , Nitric Oxide/metabolism , Ovarian Neoplasms/metabolism , Receptors, Estrogen/metabolism , Spheroids, Cellular/metabolism , Breast Neoplasms/classification , Breast Neoplasms/pathology , Female , Humans , Ovarian Neoplasms/classification , Ovarian Neoplasms/pathology , Tumor Cells, Cultured
3.
J Immunol Methods ; 474: 112671, 2019 11.
Article in English | MEDLINE | ID: mdl-31533022

ABSTRACT

Estrogen-negative (ER-) breast cancer, is recognized as an aggressive subtype, more difficult to treat, with poor survival and prognosis. They are hormonally unresponsive, with no readily effective and specific target therapy. We have previously identified Nw-hydroxy L-Arginine (NOHA) as a blood-based biomarker to distinguish between ER- and ER+ breast cancer tumors based upon disease burden, progression and molecular phenotype (U.S. Utility Patent 10,073,099). In this study we have demonstrated a competitive ELISA based assay for NOHA measurement using a proprietary monoclonal antibody (mAb) specific for NOHA (U.S. provisional patent 62/754,053). The ELISA assay was evaluated on sensitivity, selectivity, precision, dilution linearity and percent recovery parameters. The assay showed sensitivity at ≥60 pg/ml NOHA antigen with 1 ng/ml NOHA mAb, and maintained NOHA antigen specificity even in the presence of other closely related cationic amino acids (i.e. L-Arginine, D-Arginine, l-Lysine, d-Lysine, L-Ornithine, and L-Citrulline). The reliability of the ELISA protocol was confirmed with the low percent-covariance, for all tested parameters of sensitivity (≤8.2%), selectivity (≤8.6%), precision (≤12.6%), dilution linearity (≤11.2%) and recovery (≤6.7%). Additionally, we can demonstrate NOHA quantification by this ELISA assay to complement the sensitivity achievable with LC-MS (in both assay buffer and with patient plasma samples), thus suggesting it's utility as a simple yet sensitive methodology that might help in ER- breast cancer prognosis, and disease progression monitoring without the need for expensive analytical equipment (such as LC-MS), large lab space, or specialized technical training.


Subject(s)
Arginine/blood , Biomarkers, Tumor/blood , Biomarkers, Tumor/deficiency , Breast Neoplasms/blood , Breast Neoplasms/chemistry , Enzyme-Linked Immunosorbent Assay , Receptors, Estrogen/deficiency , Breast Neoplasms/pathology , Breast Neoplasms/therapy , Chromatography, High Pressure Liquid , Female , Humans , Limit of Detection , Neoplasm Staging , Predictive Value of Tests , Reproducibility of Results , Spectrometry, Mass, Electrospray Ionization
4.
Amino Acids ; 51(2): 365, 2019 02.
Article in English | MEDLINE | ID: mdl-30449003

ABSTRACT

We found a unit error with our LC-MS lower limit of quantitation (LLOQ) measurement in the Amino Acids Journal.

5.
Amino Acids ; 50(11): 1629-1636, 2018 Nov.
Article in English | MEDLINE | ID: mdl-29922922

ABSTRACT

We had shown Nw-hydroxy-L-arginine (NOHA) as a promising blood-based biomarker for estrogen-receptor-negative (ER-) breast cancer (BC) that differentiates ER- BC based on grade and molecular phenotype. In this in vitro study, we assessed the metabolic relevance for ER- BC-specific NOHA modulation and correlated them with NOHA regulatory responses. This study aids future NOHA clinical utility in ER- BC diagnosis and therapy management and would prove useful for potential drug discovery and development process.


Subject(s)
Arginine/metabolism , Breast Neoplasms/metabolism , Estrogens/metabolism , Cell Line, Tumor , Female , Humans , MCF-7 Cells , Receptors, Estrogen/metabolism
6.
Amino Acids ; 50(3-4): 373-382, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29260322

ABSTRACT

In our prior study we identified N w-hydroxy-L-arginine (NOHA) as a simple, yet sensitive indicator for estrogen negative (ER-) breast cancer early-prognosis, but not estrogen positive (ER+), and to offer ethnic selectivity for ER- detection. However, the ability of NOHA to assess ER- breast tumor based on disease progression, and tumor severity needs further delineation. Also, the overall NOHA storage stability needs to be validated. To assess the NOHA predictive capability based on disease progression, ER-/ER+ 3D-spheroids (from breast tumor cell lines of human origin) were cultured for 10 weeks. We found only ER- 3D-spheroid cultured for 10 weeks to show a gradual reduction in NOHA (both in culture medium and 3D-spheroid lysates) that correlated with a progressive increase in cellular NOS2 expression and NOS2 activity (measured as total nitrites). We additionally identified the NOHA-NOS2 correlation to be ethnically selective between ER- African American versus ER- Caucasian groups. Interestingly, such NOHA reduction was observed earlier in ER- culture medium (viz., after week 1) than from ER- 3D-spheroids lysates (viz., at the end of 3 weeks). When categorized based on 3D-spheroid grade, we found a ≥ 68% NOHA reduction in ER- spheroids that were ≤ 3 weeks old, that was categorized as "low-grade" (based on tumor size ≤ 250 µm, and with cellular characteristics identical to healthy cells). A substantial reduction in NOHA of ≥ 87% occurred with ER- 3D-spheroids grown for 6 weeks, which were categorized as "intermediate-grade" (with tumor size of ≥ 400 µm, and with less characteristic similarity to control spheroids). These in vitro findings thus suggest a distinct correlation between NOHA reduction and ER- tumor grade. Such distinctive correlation between NOHA and ER- tumor grade was additionally observed in de-identified clinical samples where a onefold higher reduction in NOHA occurred in grade-2 than with grade-1 de-identified patient plasma (when compared with control), and such correlation offered ethnic selectivity between ER- African American and ER- Caucasian groups. Of additional interest, when NOHA overall storage stability was assessed by incubating patient plasma and culture medium spiked with 75 pg/ml NOHA at multiple incubation temperatures and time-points, we found NOHA to maintain its stability for up to 6 weeks in culture medium and for 7 days in plasma at 4 °C and below. These results thus provide the first evidence of NOHA as a stable indicator to monitor ER- disease progression and tumor severity in ethnically distinctive populations.


Subject(s)
Arginine/genetics , Biomarkers, Tumor/blood , Breast Neoplasms/genetics , Receptors, Estrogen/genetics , Black or African American/genetics , Arginine/analogs & derivatives , Arginine/chemistry , Biomarkers, Tumor/genetics , Breast Neoplasms/blood , Breast Neoplasms/pathology , Cell Line, Tumor , Estrogens/genetics , Estrogens/metabolism , Ethnicity/genetics , Female , Gene Expression Regulation, Neoplastic/genetics , Humans , Nitric Oxide/metabolism , Nitric Oxide Synthase Type II/genetics , Prognosis , Spheroids, Cellular/metabolism , Spheroids, Cellular/pathology , White People/genetics
7.
Nutr Res ; 36(10): 1114-1120, 2016 10.
Article in English | MEDLINE | ID: mdl-27865353

ABSTRACT

The therapeutic benefits associated with short-term l-arginine supplementation are lost during continuous dosing. AMP-activated protein kinase (AMPK) functional modulation has been correlated with l-arginine therapeutic effectiveness, and with tolerance development during continuous supplementation. However, the metabolic link that is responsible for AMPK functional modulation during continuous l-arginine exposure is currently not known. To explore this, we incubated HUVECs for 7 days with 100 µmol/L l-arginine, in the presence or absence of other agents; and monitored their effects for eNOS function, and on tolerance sparing effects (viz, cellular glucose accumulation, and oxidative stress). HUVEC co-incubation with 100 µmol/L l-arginine and ≤1200 mg/mL calcium (Ca2+) for 7 days avoided tolerance development, with an at least 1-fold increase in the eNOS and AMPK functional activity; and an 1-fold increase in overall cellular glucose uptake. The overall cellular cytosolic Ca2+was below 200 nmol/L, with no change in cellular glucose and superoxide/peroxynitrite (O2•-/ONOO-) level from control. However, tolerance sparing effects of at least 70% decrease in eNOS and AMPK functional response, with an 1-fold reduction in glucose uptake, and at least 2-fold increase in O2•-/ONOO- were observed in cells exposed for 7 days to 100 µmol/L l-arginine at Ca2+co-incubation concentration of >1200 mg/mL. The >1200 mg/mL Ca2+ co-incubation condition, also improved the overall cellular Ca2+to >200 nmol/L. Similar tolerance response was observed in cells co-treated with 100 µmol/L l-arginine and ≤1200 mg/mL Ca2+ in the presence of Ca2+ influx inhibitor (20 µmol/L 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid), or eNOS activity inhibitor (30 µmol/L l-NG-nitroarginine methyl ester). No tolerance response was seen in cells incubated for 7 days with 100 µmol/L l-arginine and ≤1200 mg/mL Ca2+; even in the presence of the inhibitor for cellular glucose induction (30 µmol/L 5-chloro-2-(n-(2,5-dichlorobenzenesulfonamide))-benzoxazole). The present study thus provides the first definitive evidence that shows the need to maintain cytosolic Ca2+ within a threshold limit of less than 200 nmol/L to extend l-arginine therapeutic efficacy during continuous dosing, without any potential tolerance development.


Subject(s)
AMP-Activated Protein Kinases/metabolism , Arginine/administration & dosage , Calcium, Dietary/therapeutic use , Calcium/metabolism , Drug Tolerance , Nitric Oxide Synthase Type III/metabolism , Nitric Oxide/metabolism , Arginine/pharmacology , Arginine/therapeutic use , Calcium, Dietary/metabolism , Calcium, Dietary/pharmacology , Dietary Supplements , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Glucose/metabolism , Human Umbilical Vein Endothelial Cells , Humans , Oxidative Stress , Peroxynitrous Acid/metabolism , Phosphorylation , Superoxides/metabolism
8.
Amino Acids ; 48(11): 2693-2698, 2016 11.
Article in English | MEDLINE | ID: mdl-27503558

ABSTRACT

As a heterogeneous disease, breast cancer can be divided into distinct subtypes. Among the two major subsets of estrogen receptor-negative (ER-) and ER-positive (ER+) tumors, the ER- is a more aggressive subtype, more difficult to treat, has greater ethnic disparity concerns, worse prognosis, and almost twice the risk of mortality. We provide here a fundamental delineation of N w-hydroxy-L-arginine as a sensitive and reliable ethnic specific indicator for ER- breast cancer early-prognosis (United States provisional patent application number 62232816).


Subject(s)
Arginine/analogs & derivatives , Arginine/metabolism , Biomarkers, Tumor/metabolism , Breast Neoplasms/ethnology , Breast Neoplasms/metabolism , Receptors, Estrogen , Female , Humans , MCF-7 Cells
9.
Nutr Metab (Lond) ; 10(1): 40, 2013 May 29.
Article in English | MEDLINE | ID: mdl-23718875

ABSTRACT

BACKGROUND: Our prior study revealed the loss in short-term L-Arginine (ARG) therapeutic efficacy after continuous exposure; resulting in tolerance development, mediated by endothelial nitric oxide synthase (eNOS) down-regulation, secondary to oxidative stress and induced glucose accumulation. However, the potential factor regulating ARG cellular response is presently unknown. METHOD: Human umbilical vein endothelial cells were incubated with 100 µM ARG for 2 h in buffer (short-term or acute), or for 7 days in culture medium and challenged for 2 h in buffer (continuous or chronic), in the presence or absence of other agents. eNOS activity was determined by analyzing cellular nitrite/nitrate (NO2-/NO3-), and AMP-activated protein kinase (AMPK) activity was assayed using SAMS peptide. 13C6 glucose was added to medium to measure glucose uptake during cellular treatments, which were determined by LC-MS/MS. Cellular glucose was identified by o-toluidine method. Superoxide (O2•-) was identified by EPR-spin-trap, and peroxynitrite (ONOO-) was measured by flow-cytometer using aminophenyl fluorescein dye. RESULTS: Short-term incubation of cells with 100 µM ARG in the presence or absence of 30 µM L-NG-Nitroarginine methyl ester (L-NAME) or 30 µM AMPK inhibitor (compound C, CMP-C) increased cellular oxidative stress and overall glucose accumulation with no variation in glucose transporter-1 (GLUT-1), or AMPK activity from control. The increase in total NO2-/NO3- after 2 h 100 µM ARG exposure, was suppressed in cells co-incubated with 30 µM CMP-C or L-NAME. Long-term exposure of ARG with or without CMP-C or L-NAME suppressed NO2-/NO3-, glucose uptake, GLUT-1, AMPK expression and activity below control, and increased overall cellular glucose, O2•- and ONOO-. Gluconeogenesis inhibition with 30 µM 5-Chloro-2-N-2,5-dichlorobenzenesulfonamido-benzoxazole (CDB) during ARG exposure for 2 h maintained overall cellular glucose to control, but increased cellular glucose uptake. Continuous co-incubation with CDB and ARG increased NO2-/NO3-, glucose uptake, GLUT-1, AMPK expression and activity, and maintained overall cellular glucose, O2•- and ONOO- to control conditions. CONCLUSION: The present study provides the fundamental evidence for AMPK as the primary modulator of ARG cellular responses and for regulating the mode of glucose accumulation during short-term and continuous ARG treatments.

10.
Int J Mol Sci ; 13(6): 7521-7531, 2012.
Article in English | MEDLINE | ID: mdl-22837709

ABSTRACT

The mechanism by which asymmetric dimethylarginine (ADMA) induces vascular oxidative stress is not well understood. In this study, we utilized human umbilical vein endothelial cells (HUVEC) to examine the roles of ADMA cellular transport and the uncoupling of endothelial nitric oxide synthase (eNOS) in contributing to this phenomenon. Dihydroethidium (DHE) fluorescence was used as an index of oxidative stress. Whole cells and their isolated membrane fractions exhibited measureable increased DHE fluorescence at ADMA concentrations greater than 10 µM. ADMA-induced DHE fluorescence was inhibited by co-incubation with L-lysine, tetrahydrobiopterin (BH(4)), or L-nitroarginine methyl ester (L-NAME). Oxidative stress induced in these cells by angiotensin II (Ang II) were unaffected by the same concentrations of L-lysine, L-NAME and BH(4). ADMA-induced reduction in cellular nitrite or nitrite/nitrate production was reversed in the presence of increasing concentrations of BH(4). These results suggest that ADMA-induced DHE fluorescence involves the participation of both the cationic transport system in the cellular membrane and eNOS instead of the Ang II-NADPH oxidase pathway.


Subject(s)
Arginine/analogs & derivatives , Enzyme Inhibitors/pharmacology , Human Umbilical Vein Endothelial Cells/metabolism , Oxidative Stress/drug effects , Arginine/pharmacology , Biopterins/analogs & derivatives , Biopterins/pharmacology , Human Umbilical Vein Endothelial Cells/cytology , Humans , Lysine/pharmacology , NG-Nitroarginine Methyl Ester/pharmacology , Nitrates/metabolism , Nitric Oxide Synthase Type III/antagonists & inhibitors , Nitric Oxide Synthase Type III/metabolism , Nitrites/metabolism
11.
Amino Acids ; 43(3): 1179-88, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22130739

ABSTRACT

The therapeutic benefits of L-arginine (ARG) supplementation in humans, often clearly observed in short-term studies, are not evident after long-term use. The mechanisms for the development of ARG tolerance are not known and cannot be readily examined in humans. We have developed a sensitive in vitro model using a low glucose/low arginine culture medium to study the mechanisms of ARG action and tolerance using two different human endothelial cells, i.e., Ea.hy926 and human umbilical venous endothelial cells. Cultured cells were incubated with different concentrations of ARG and other agents to monitor their effects on endothelial nitric oxide synthase (eNOS) expression and function, as well as glucose and superoxide (O2(·-) ) accumulation. Short-term (2 h) exposure to at least 50 µM ARG moderately increased eNOS activity and intracellular glucose (p < 0.05), with no change in eNOS mRNA or protein expression. In contrast, 7-day continuous ARG exposure suppressed eNOS expression and activity. This was accompanied by increase in glucose and O2(·-) accumulation. Co-incubation with 100 µM ascorbic acid, 300 U/ml polyethylene glycol-superoxide dismutase (PEG-SOD), 100 µM L-lysine or 30 µM 5-chloro-2-(N-2,5-dichlorobenenesulfonamido)-benzoxazole (a fructose-1,6-bisphosphatase inhibitor) prevented the occurrence of cellular ARG tolerance. Short-term co-incubation of ARG with PEG-SOD improved cellular nitrite accumulation without altering cellular ARG uptake. These studies suggest that ARG-induced oxidative stress may be a primary causative factor for the development of cellular ARG tolerance.


Subject(s)
Arginine/pharmacology , Drug Tolerance , Human Umbilical Vein Endothelial Cells/drug effects , Oxidative Stress/drug effects , Arginase/metabolism , Arginine/analogs & derivatives , Arginine/metabolism , Ascorbic Acid/pharmacology , Cells, Cultured , Citrulline/metabolism , Culture Media , Down-Regulation/drug effects , Free Radical Scavengers/pharmacology , Gene Expression/drug effects , Glucose/metabolism , Human Umbilical Vein Endothelial Cells/enzymology , Human Umbilical Vein Endothelial Cells/metabolism , Humans , Nitrates/metabolism , Nitric Oxide Synthase Type III/genetics , Nitric Oxide Synthase Type III/metabolism , Nitrites/metabolism , Polyethylene Glycols/pharmacology , Superoxide Dismutase/pharmacology , Superoxides/metabolism
12.
Biochem Biophys Res Commun ; 414(4): 660-3, 2011 Nov 04.
Article in English | MEDLINE | ID: mdl-21986532

ABSTRACT

We examined the relative contributory roles of extracellular vs. intracellular L-arginine (ARG) toward cellular activation of endothelial nitric oxide synthase (eNOS) in human endothelial cells. EA.hy926 human endothelial cells were incubated with different concentrations of (15)N(4)-ARG, ARG, or L-arginine ethyl ester (ARG-EE) for 2h. To modulate ARG transport, siRNA for ARG transporter (CAT-1) vs. sham siRNA were transfected into cells. ARG transport activity was assessed by cellular fluxes of ARG, (15)N(4)-ARG, dimethylarginines, and L-citrulline by an LC-MS/MS assay. eNOS activity was determined by nitrite/nitrate accumulation, either via a fluorometric assay or by(15)N-nitrite or estimated (15)N(3)-citrulline concentrations when (15)N(4)-ARG was used to challenge the cells. We found that ARG-EE incubation increased cellular ARG concentration but no increase in nitrite/nitrate was observed, while ARG incubation increased both cellular ARG concentration and nitrite accumulation. Cellular nitrite/nitrate production did not correlate with cellular total ARG concentration. Reduced (15)N(4)-ARG cellular uptake in CAT-1 siRNA transfected cells vs. control was accompanied by reduced eNOS activity, as determined by (15)N-nitrite, total nitrite and (15)N(3)-citrulline formation. Our data suggest that extracellular ARG, not intracellular ARG, is the major determinant of NO production in endothelial cells. It is likely that once transported inside the cell, ARG can no longer gain access to the membrane-bound eNOS. These observations indicate that the "L-arginine paradox" should not consider intracellular ARG concentration as a reference point.


Subject(s)
Arginine/metabolism , Endothelium, Vascular/metabolism , Nitric Oxide/biosynthesis , Arginine/analysis , Arginine/pharmacology , Cationic Amino Acid Transporter 1/genetics , Cationic Amino Acid Transporter 1/metabolism , Cell Line , Endothelium, Vascular/chemistry , Endothelium, Vascular/drug effects , Humans , Nitric Oxide/analysis , Nitric Oxide Synthase Type III/metabolism , RNA, Small Interfering/genetics , Transfection
13.
J Chromatogr B Analyt Technol Biomed Life Sci ; 879(7-8): 467-74, 2011 Mar 01.
Article in English | MEDLINE | ID: mdl-21282076

ABSTRACT

PURPOSE: L-Arginine (ARG) is converted to nitric oxide (NO) and L-citrulline (CIT) by endothelial nitric oxide synthase which is competitively inhibited by asymmetric dimethylarginine (ADMA). We have developed a liquid chromatography-mass spectrometric method for the simultaneous determination of endogenous ARG, labeled ARG (¹5N4-ARG), CIT, ADMA, and its inactive isomer, symmetric dimethylarginine (SDMA) in biological samples. METHODS: Concentrations of unlabeled ARG, ¹5N4-ARG, CIT, ADMA, and SDMA in EA.hy926 human endothelial cell lysate, cell incubation media, rat plasma or rat urine were measured by hydrophilic-interaction liquid chromatography electrospray tandem mass spectrometry. ¹³C6-ARG, D4-CIT and D7-ADMA were used as internal standards for ARG and ¹5N4-ARG, CIT, and dimethylarginines, respectively. RESULTS: The calibration curves of ARG, ¹5N4-ARG, CIT, ADMA, and SDMA were linear and independent of several sample matrices. Intra- and inter-day variabilities for the quantification of all the compounds were below 15% in quality control samples. Application of this method to determine the uptake as well as efflux of these compounds was illustrated through in vitro cell study by exposing human endothelial cells to ¹5N4-ARG, which allowed the observation of generation of ¹5N3-CIT and ¹5N3-ARG in the cell lyate. Use of these isotopes adds insights into the cellular handling of endogenous vs. exogenous ARG. Application of this method for rat plasma and rat urine assays was demonstrated after ARG oral supplementation in rats. CONCLUSION: An LC-MS/MS method was developed to quantify 6 ARG-related compounds simultaneously, utilizing 3 separate internal standards. This assay allows concurrent monitoring of uptake, efflux and metabolic processes when isotope-labeled ARG and CIT are measured, and can be applied for determination of these compounds in rat plasma and rat urine.


Subject(s)
Arginine/analogs & derivatives , Arginine/analysis , Chromatography, Liquid/methods , Citrulline/analysis , Tandem Mass Spectrometry/methods , Animals , Arginine/pharmacokinetics , Cell Line , Citrulline/pharmacokinetics , Drug Stability , Extracellular Space/chemistry , Humans , Male , Nitrogen Isotopes , Rats , Rats, Sprague-Dawley , Reproducibility of Results , Sensitivity and Specificity
14.
PLoS One ; 3(3): e1786, 2008 Mar 12.
Article in English | MEDLINE | ID: mdl-18335057

ABSTRACT

When caterpillars feed on maize (Zea maize L.) lines with native resistance to several Lepidopteran pests, a defensive cysteine protease, Mir1-CP, rapidly accumulates at the wound site. Mir1-CP has been shown to inhibit caterpillar growth in vivo by attacking and permeabilizing the insect's peritrophic matrix (PM), a structure that surrounds the food bolus, assists in digestion and protects the midgut from microbes and toxins. PM permeabilization weakens the caterpillar defenses by facilitating the movement of other insecticidal proteins in the diet to the midgut microvilli and thereby enhancing their toxicity. To directly determine the toxicity of Mir1-CP, the purified recombinant enzyme was directly tested against four economically significant Lepidopteran pests in bioassays. Mir1-CP LC(50) values were 1.8, 3.6, 0.6, and 8.0 ppm for corn earworm, tobacco budworm, fall armyworm and southwestern corn borer, respectively. These values were the same order of magnitude as those determined for the Bacillus thuringiensis toxin Bt-CryIIA. In addition to being directly toxic to the larvae, 60 ppb Mir1-CP synergized sublethal concentrations of Bt-CryIIA in all four species. Permeabilization of the PM by Mir1-CP probably provides ready access to Bt-binding sites on the midgut microvilli and increases its activity. Consequently, Mir1-CP could be used for controlling caterpillar pests in maize using non-transgenic approaches and potentially could be used in other crops either singly or in combination with Bt-toxins.


Subject(s)
Bacillus thuringiensis/metabolism , Bacterial Toxins/toxicity , Cysteine Endopeptidases/toxicity , Lepidoptera/physiology , Zea mays/enzymology , Animals , Cysteine Endopeptidases/metabolism , Dose-Response Relationship, Drug
SELECTION OF CITATIONS
SEARCH DETAIL
...